Stevens-Johnson syndrome in children.
Journal
Current opinion in pediatrics
ISSN: 1531-698X
Titre abrégé: Curr Opin Pediatr
Pays: United States
ID NLM: 9000850
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
entrez:
15
7
2022
pubmed:
16
7
2022
medline:
19
7
2022
Statut:
ppublish
Résumé
The concept of Stevens-Johnson syndrome (SJS) in children is evolving. This manuscript reviews recent advances with the lens of new terminology namely infection-triggered reactive infectious mucocutaneous eruption and drug-induced epidermal necrolysis, with the objective of integrating this novel terminology practically. Traditionally considered to exist on a spectrum with toxic epidermal necrolysis, SJS in children is more often caused or triggered by infections instead of medications. Proposed pediatric-specific terminology can be applied to literature to gain further insights into blistering severe cutaneous adverse reactions. Distinguishing infection-triggered from drug-triggered blistering reactions is useful for 3 main reasons: (1) early clinically recognizable different features such as isolated or predominant mucositis, (2) different initial management depending on trigger, (3) avoiding the label of a drug reaction on cases triggered by infection.
Identifiants
pubmed: 35836393
doi: 10.1097/MOP.0000000000001146
pii: 00008480-202208000-00009
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-348Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92–96.
Ramien ML, Bahubeshi A, Lara-Corrales I, et al. Blistering severe cutaneous adverse reactions in children: proposal for pediatric-focused clinical criteria. Brit J Dermatol 2021; 185:447–449.
Ramien ML. Reactive infectious mucocutaneous eruption: mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol 2021; 46:420–429.
Rendu R. Sur un syndrome caractérisé par une l’inflammation simultanée de toutes les muqueuses externes (conjonctivale, nasale, linguale, buccopharyngée, anale et balano-prépuciale) coexistant avec une éruption varicelliforme puis purpurique des quatre membres. J Prat 1916; 30:351–352.
Fiessenger N, Rendu R. Sur un syndrome caractérisé par l’inflammation simultanée de toutes les muqueuses externes coexistant avec une éruption vésiculeuse des quatre membres, non douloureuse et non récidivante. Paris Méd 1917; 25:54–58.
Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983; 8:763–775.
Fuchs E. Herpes oris conjunctivae. Klin Monatsbl Augenheilkd 1876; 14:333–351.
Havliza K, Jakob A, Rompel R. Erythema multiforme majus (Fuchs syndrome) associated with Mycoplasma pneumoniae infection in two patients. J Dtsch Dermatol Ges 2009; 7:445–448.
Vanfleteren I, Gysel DV, Brandt CD. Stevens-Johnson syndrome: a diagnostic challenge in the absence of skin lesions. Pediatr Dermatol 2003; 20:52–56.
Schalock PC, Dinulos JGH. ‘Atypical’ Stevens-Johnson syndrome? Pediatrics 2007; 120: 451-2, author reply 452.
Schalock PC, Dinulos JGH. Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: fact or fiction? J Am Acad Dermatol 2005; 52:312–315.
Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol 2015; 72:239–245.
Stanyon JH, Warner WP. Mucosal respiratory syndrome. Can Med Assoc J 1945; 53:427–434.
Mayor-Ibarguren A, Feito-Rodriguez M, González-Ramos J, et al. Mucositis secondary to Chlamydia pneumoniae infection: expanding the mycoplasma pneumoniae-induced rash and mucositis concept. Pediatr Dermatol 2017; 34:465–472.
McPherson T, Exton LS, Biswas S, et al. British Association of Dermatologists’ guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people. Brit J Dermatol 2019; 181:37–54.
Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol 2018; 35:182–187.
Hsu DY, Brieva J, Silverberg NB, Paller AS, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 2017; 76:811–817.e4.
Peter JG, Lehloenya R, Dlamini S, et al. Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice. J Allergy Clin Immunol Pract 2017; 5:547–563.
White KD, Chung WH, Hung SI, et al. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response. J Allergy Clin Immunol 2015; 136: 136: 219-34, quiz 235.
Forsyth J, Russell E, McPherson T. A retrospective case series of paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: evaluation of practice using the British Association of Dermatology's National Guidelines for children and young people. Brit J Dermatol 2022; 186:197–198.
Holcomb ZE, Hussain S, Huang JT, Delano S. Reactive infectious mucocutaneous eruption associated with SARS-CoV-2 infection. JAMA Dermatol 2021; 157:603–605.
Song A, Nicholson C, Maguiness S. Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS-CoV-2 and influenza A. Pediatr Dermatol 2021; 38:1222–1225.
Giraud-Kerleroux L, Bellon N, Welfringer-Morin A, et al. Childhood epidermal necrolysis and erythema multiforme major: a multicentre French cohort study of 62 patients. J Eur Acad Dermatol 2021; 35:2051–2058.
Eliades P, Fonseca M, Harp J. Use of etanercept in a series of pediatric patients with stevens-johnson syndrome-toxic epidermal necrolysis spectrum disease. JAMA Dermatol 2020; 156:921–922.
Bitar C, Chan MP, Harms PW, et al. Cutaneous manifestations of hospitalized coronavirus disease 2019 patients: a report of six cases with clinicopathologic features and viral RNA in situ hybridization. J Eur Acad Dermatol 2020; 34:e656–e659.
Goyal A, Hook K. Two pediatric cases of influenza B-induced rash and mucositis: Stevens-Johnson syndrome or expansion of the Mycoplasma pneumoniae-induced rash with mucositis (MIRM) spectrum? Pediatr Dermatol 2019; 32:472.
Su JR, Haber P, Ng CS, et al. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999–2017. Vaccine 2020; 38:1746–1752.
Garg T, Sanke S, Ahmed R, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like cutaneous presentation of chikungunya fever: a case series. Pediatr Dermatol 2018; 35:392–396.
Olson D, Abbott J, Lin C, et al. Characterization of children with recurrent episodes of Stevens Johnson syndrome. J Pediatric Infect Dis Soc 2017; 6:e140–e143.
Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol 2015; 29:595–598.
Schalock PC, Thyssen JP, Dinulos JGH. Mycoplasma pneumoniae-associated mucositis: by any other name is not so sweet. Pediatr Dermatol 2012; 29:392–1392.
Brunet-Possenti F, Steff M, Marinho E, et al. (Stevens-Johnson syndrome concurrent with primary Epstein-Barr virus infection). Ann Dermatol Venereol 2013; 140:112–115.
Maggio MC, Liotta A, Cardella F, Corsello G. Stevens-Johnson syndrome and cholestatic hepatitis induced by acute Epstein-Barr virus infection. Eur J Gastroenterol Hepatol 2011; 23:289–1289.
Duarte AF, Cruz MJ, Moreira E, et al. Stevens-Johnson syndrome/erythema multiforme major and Chlamydia pneumoniae infection in young patients. Dermatol Rep 2010; 2:e6–e16.
Bay A, Akdeniz N, Calka O, et al. Primary varicella infection associated with Stevens-Johnson syndrome in a Turkish child. J Dermatol 2005; 32:745–750.
Prais D, Grisuru-Soen G, Barzilai A, Amir J. Varicella zoster virus infection associated with erythema multiforme in children. Infection 2001; 29:37–39.
Werblowsky-Constantini N, Livshin R, Burstein M, et al. Toxic epidermal necrolysis associated with acute cholestatic viral hepatitis A. J Clin Gastroenterol 1989; 11:691–693.
Mardani M, Mardani S, Kani ZA, Hakamifard A. An extremely rare mucocutaneous adverse reaction following COVID-19 vaccination: toxic epidermal necrolysis. Dermatol Ther 2022; 35:e15416.
Mansouri P, Farshi S. A case of Steven-Johnson syndrome after COVID-19 vaccination. J Cosmet Dermatol 2022; 21:1358–1360.
Dash S, Sirka CS, Mishra S, Viswan P. COVID-19 vaccine induced Steven-Johnson syndrome: a case report. Clin Exp Dermatol 2021; 46:1615–1617.
Battaglini D, Ball L, Robba C, et al. Patients with suspected severe adverse reactions to COVID-19 vaccination admitted to intensive care unit: a case report. Front Med 2022; 9:823837.
Aimo C, Mariotti EB, Corrà A, et al. Stevens-Johnson syndrome induced by Vaxvetria (AZD1222) COVID-19 vaccine. J Eur Acad Dermatol 2022; 36:e417–e419.
Tong J, Chan J. Stevens-Johnson syndrome due to influenza vaccination. Cureus 2020; 12:e9405.
Kunimi Y, Hirata Y, Aihara M, et al. Statistical analysis of Stevens-Johnson syndrome caused by Mycoplasma pneumonia infection in Japan. Allergol Int 2011; 60:525–532.
Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17:697–728.
Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am 2011; 53:e25–e76.
Sauteur PMM, Trück J, Rossum AMC van, Berger C. Circulating antibody-secreting cell response during Mycoplasma pneumoniae childhood pneumonia. J Infect Dis 2020; 222:136–147.
Narita M. Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol 2016; 7:1–9. article 23.
Wang Y, Zhang Y, Lu W, Wang L. Serum tumor necrosis factor-α and interferon-γ levels in pediatric Mycoplasma pneumoniae pneumonia: a systematic review and meta-analysis. Can Respir J 2018; 2018:8354892–8354896.
Sauteur PMM, Theiler M, Buettcher M, et al. Frequency and clinical presentation of mucocutaneous disease due to Mycoplasma pneumoniae infection in children with community-acquired pneumonia. JAMA Dermatol 2020; 156:144–150.
Olson D, Watkins LKF, Demirjian A, et al. Outbreak of Mycoplasma pneumoniae-associated Stevens-Johnson syndrome. Pediatrics 2015; 136:e386–e394.
Iwai S, Sueki H, Watanabe H, et al. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically. J Dermatol 2012; 39:781–786.
Wang L, Hong KC, Lin FC, Yang KD. Mycoplasma pneumoniae-associated Stevens-Johnson syndrome exhibits lymphopenia and redistribution of CD4+ T cells. J Formos Medical Assoc 2003; 102:55–58.
Brazel D, Kulp B, Bautista G, Bonwit A. Rash and mucositis associated with Mycoplasma pneumoniae and Chlamydophila pneumoniae : a recurrence of MIRM? J Pediatric Infect Dis Soc 2021; 10:220–224.
Liakos W, Xu A, Finelt N. Clinical features of recurrent Mycoplasma pneumoniae -induced rash and mucositis. Pediatr Dermatol 2021; 38:154–158.
Mazori DR, Nagarajan S, Glick SA. Recurrent reactive infectious mucocutaneous eruption (RIME): Insights from a child with three episodes. Pediatr Dermatol 2020; 37:545–547.
Abtahi-Naeini B, Dehghan MS, Paknazar F, et al. Clinical and epidemiological features of patients with drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Iran: different points of children from adults. Int J Pediatrics 2022; 2022:8163588.
Gleghorn KL, Voigt C, Kelly B. Toxic epidermal necrolysis and Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: A 25-year retrospective study at a single tertiary care center. Pediatr Dermatol 2021; 38:812–818.
Sibbald C, Putterman E, Micheletti R, et al. Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediatr Dermatol 2020; 37:461–466.
Oh HL, Kang DY, Kang HR, et al. Severe cutaneous adverse reactions in Korean pediatric patients: a study from the Korea SCAR Registry. Allergy Asthma Immunol Res 2019; 11:241–253.
Misirlioglu ED, Guvenir H, Bahceci S, et al. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract 2017; 5:757–763.
Quirke KP, Beck A, Gamelli RL, Mosier MJ. A 15-year review of pediatric toxic epidermal necrolysis. J Burn Care Res 2015; 36:130–136.
Paulmann M, Mockenhaupt M. Fever in Stevens-Johnson Syndrome and toxic epidermal necrolysis in pediatric cases: laboratory work-up and antibiotic therapy. Pediatr Infecti Dis J 2017; 36:513–515.
Ramien ML, Bruckner AL. mucocutaneous eruptions in acutely ill pediatric patients-think of Mycoplasma pneumoniae (and other infections) first. JAMA Dermatol 2020; 156:124–125.
Chafranska L, Saunte DM, Behrendt N, et al. Pediatric toxic epidermal necrolysis treated successfully with infliximab. Pediatr Dermatol 2019; 36:342–345.
Song H, Huang JT, Tan JK. Mycoplasma-induced rash and mucositis in a father and son: a case report. Pediatric Infect Dis J 2018; 37:e205–e206.
Sorrell J, Anthony L, Rademaker A, et al. Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis. Pediatr Dermatol 2017; 34:433–437.
Dondi A, Altobrando AD, Parladori R, et al. Duck-like lips: a new clinical feature for diagnosis of Mycoplasma-Induced Rash and Mucositis. J Eur Acad Dermatol 2021; 35:e225–e227.
Shanbhag SS, Rashad R, Chodosh J, Saeed HN. Long-term effect of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Ophthalmol 2019; 208:331–341.
Shah PR, Williams AM, Pihlblad MS, Nischal KK. Ophthalmic manifestations of Mycoplasma-induced rash and mucositis. Cornea 2019; 38:1305–1308.
Jin HD, Siatkowski RM, Siatkowski RL. Ocular manifestations of mycoplasma-induced rash and mucositis. J AAPOS 2020; 24:249–251.
Kohanim S, Palioura S, Saeed HN, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis – a comprehensive review and guide to therapy. II. Ophthalmic disease. Ocular Surf 2016; 14:168–188.
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60–68.
Pichler WJ. Immune mechanism of drug hypersensitivity. Immunol Allergy Clin N Am 2004; 24:373–397. v-vi.
O’Brien KF, Saardi KM, Johnson LS, et al. Recommendations for prevention of drug re-exposure in toxic epidermal necrolysis. J Drugs Dermatol 2019; 18:1049–1052.
Beck A, Quirke KP, Gamelli RL, Mosier MJ. Pediatric toxic epidermal necrolysis: using SCORTEN and predictive models to predict morbidity when a focus on mortality is not enough. J Burn Care Res 2015; 36:167–177.
Fujimoto A, Iwai Y, Ishikawa T, et al. Deep neural network for early image diagnosis of stevens-johnson syndrome/toxic epidermal necrolysis. J Allergy Clin Immunol Pract 2022; 10:277–283.
Brüggen MC, Le ST, Walsh S, et al. Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus. Br J Dermatol 2021; 185:616–626.
Porebski G, Piotrowicz-Wojcik K, Spiewak R. ELISpot assay as a diagnostic tool in drug hypersensitivity reactions. J Immunol Methods 2021; 495:113062doi: 10.1016/j.jim.2021.113062.
doi: 10.1016/j.jim.2021.113062
Liccioli G, Filippeschi C, Giovannini M, et al. Mycoplasma pneumoniae-associated mucocutaneous disease in children: a case series with allergy workup in a tertiary-care paediatric hospital. Clin Exp Allergy 2021; 51:740–744.
Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev 2022; 3:CD013130.
Antoon JW, Goldman JL, Shah SS, Lee B. A retrospective cohort study of the management and outcomes of children hospitalized with Stevens-Johnson syndrome or toxic epidermal necrolysis. J Allergy Clin Immunol Pract 2019; 7:244–250.e1.
Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2017; 153:514–522.
Pozzo-Magana BRD, Lazo-Langner A, Carleton B, et al. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol 2011; 18:e121–e133.
Struck MF, Hilbert P, Mockenhaupt M, et al. Severe cutaneous adverse reactions: emergency approach to nonburn epidermolytic syndromes. Intensive Care Med 2010; 36:22–32.
Miller MM, Kamath S, Hughes M, et al. Evaluation of etanercept for treatment of reactive infectious mucocutaneous eruption. JAMA Dermatol 2021; 157:230–232.
Li HOY, Colantonio S, Ramien ML. Treatment of Mycoplasma pneumoniae-induced rash and mucositis with cyclosporine. J Cutan Med Surg 2019; 23:608–612.
John JS, Ratushny V, Liu KJ, et al. Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol 2017; 34:540–546.
Sachdeva M, Mufti A, Kim P, et al. Biologic treatment in pediatric Stevens-Johnson Syndrome/toxic epidermal necrolysis: a systematic review. J Am Acad Dermatol 2021; 85:1011–1013.
Gise R, Elhusseiny AM, Scelfo C, Mantagos IS. Mycoplasma Pneumoniae-induced rash and mucositis: a longitudinal perspective and proposed management criteria. Am J Ophthalmol 2020; 219:351–356.
Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology 2016; 123:1653–1658.
Ingen-Housz-Oro S, Alves A, Colin A, et al. Health-related quality of life and long-term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. Br J Dermatol 2020; 182:916–926.
Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol 2017; 177:924–935.
Chen CB, Abe R, Pan RY, et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res 2018; 2018:6431694.